Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Lancet Infect Dis. 2016 Mar 10;16(7):809–818. doi: 10.1016/S1473-3099(16)00074-8

Figure 1. Flowchart of study participation.

Figure 1

A total of 172 individuals with HIV-associated cryptococcal meningitis were enrolled in the study. This reflects N=60 participants being evaluated for safety and tolerability of adjunctive sertraline and additional N=112 participants that either underwent a ‘mock’ randomization of open-labeled sertraline (N=96; participants with first-episode of cryptococcal meningitis) or received 200mg daily of adjunctive sertraline for second episode of cryptococcal meningitis (N=16).